Clinical Trials on Gestational Diabetes in India

Total 520 results

Novo Nordisk A/S

Completed

Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

India, Italy, United Kingdom, Finland, Japan, Argentina, Macedonia, The Former Yugoslav Republic of, Brazil
Novo Nordisk A/S

Completed

Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes (EFFICACY)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Argentina, Thailand, India, Korea, Republic of
Novo Nordisk A/S

Completed

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Canada, Germany, Netherlands, Argentina, Finland, Serbia, Mexico
AstraZeneca
Bristol-Myers Squibb

Completed

52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period

Type 2 Diabetes

Korea, Republic of, Russian Federation, United Kingdom, Vietnam, Germany, Hungary, Finland, Norway, Netherlands, Slovakia, India
AstraZeneca

Terminated

GALLANT 8 Tesaglitazar Add-on to Metformin

Type 2 Diabetes

Italy, United Kingdom, Germany, Philippines, Malaysia, Sweden, Finland, Canada, India, Australia, Singapore
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Diabetes Mellitus, Type 2

United States, France, India, Philippines
Novo Nordisk A/S

Completed

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes (LIRA-PRIME)

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada, Serbia, Turkey, Russian Federation, India, Latvia, Puerto Rico, Lebanon, Colombia
Novo Nordisk A/S

Completed

A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice (ARISE)

Diabetes Mellitus, Type 2

Malaysia, South Africa, Philippines, Australia, India, Saudi Arabia
Takeda

Completed

Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States, Australia, Brazil, Guatemala, India, Mexico, New Zealand, Peru, South Africa, Czech Republic, Germany, Hungary, Netherlands, Argentina
Takeda

Completed

Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

Type 2 Diabetes Mellitus

United States, Australia, Brazil, Bulgaria, Chile, Croatia, Estonia, Guatemala, India, Israel, Latvia, Mexico, New Zealand, Peru, Romania, Russian Federation, Serbia, South Africa, Ukraine
Novo Nordisk A/S

Withdrawn

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

Thailand, Malaysia, Poland, India, Hungary, Mexico, Brazil, United States, Croatia, Romania, Bulgaria, Greece, Serbia
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus (DUALTM IX)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Canada, Spain, Switzerland, Argentina, Finland, Hungary, Russian Federation, Slovenia, Slovakia
Novo Nordisk A/S

Terminated

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin (iDEAt2)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Mexico, Israel, Taiwan, Malaysia, Hungary, Turkey, Morocco, Germany, South Africa, Portugal, Lebanon, Italy, Brazil, Croatia, Egypt, Spain, Russian Federation, Greece, Argentina, Korea, Republic of, Poland, Serbia
Novo Nordisk A/S

Completed

Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Argentina, Turkey, Canada, South Africa, Mexico
Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes (LEAD-1)

Diabetes Mellitus, Type 2 | Diabetes

Israel, Poland, Switzerland, Argentina, India, Malaysia, South Africa, Taiwan, Finland, France, Turkey, Croatia, Italy, Bulgaria, Romania, Australia, Thailand, Greece, Brazil, Spain, Korea, Republic of, Czech Republic, Philippines
AstraZeneca

Completed

A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In T2DM (INSIGHT)

Type II Diabetes Mellitus

India
Novartis Pharmaceuticals

Completed

Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

Type II Diabetes Mellitus | Congestive Heart Failure

Russian Federation, Singapore, Italy, Czechia, Lithuania, Germany, Guatemala, India, Denmark, Estonia, Slovakia, Romania, Latvia, Greece, Poland
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (SURMOUNT-2)

Obesity | Overweight | Type 2 Diabetes

United States, Russian Federation, Taiwan, Argentina, Brazil, Japan, Puerto Rico, India
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN 8)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, United Kingdom, Canada, Sweden, Ireland, Argentina, Brazil, Lebanon, Malaysia, Mexico, Italy
Pfizer

Completed

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

Diabetes Mellitus, Type 2

Taiwan, United States, Hungary, Canada, Slovakia, India, Bulgaria
AstraZeneca

Completed

Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin

Type 2 Diabetes

Mexico, United States, Poland, Canada, Russian Federation, South Africa, France, Hungary, India, United Kingdom
AtheroGenics

Unknown

ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study (ANDES)

Diabetes

United States, Ukraine, India, South Africa, Bosnia and Herzegovina, Former Serbia and Montenegro, Georgia, Macedonia, The Former Yugoslav Republic of
Novo Nordisk A/S

Completed

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin (LIRA-SWITCH™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Canada, Hungary, India, Spain, Puerto Rico
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin (PIONEER 8)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Japan, Puerto Rico, Canada, France, Mexico, Poland, Russian Federation, Greece
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)

Diabetes Mellitus, Type 2 | Renal Insufficiency

Spain, Canada, France, Germany, Australia, Costa Rica, Finland, Russian Federation, Argentina, India, Norway, Sweden
Janssen Research & Development, LLC

Completed

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

France, Poland, United Kingdom, United States, Spain, Colombia, India, Romania, South Africa, Ukraine, Australia, Canada, Greece, Sweden, New Zealand, Switzerland, Hong Kong
AstraZeneca
Astra Zeneca, Bristol-Myers Squibb

Completed

Add-on to Thiazolidinedione (TZD) Failures

Type 2 Diabetes

Taiwan, United States, Argentina, Canada, Mexico, Puerto Rico, Philippines, India, Peru
Eli Lilly and Company

Completed

A Study for Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Puerto Rico, United States, Romania, United Kingdom, Spain, Mexico, Austria, South Africa, Germany, Ukraine, India
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Nutritional and Metabolic Diseases

United Kingdom, Germany, Belgium, Poland, India, Finland, Sweden, Netherlands, Russian Federation, Norway, Denmark
Novo Nordisk A/S

Completed

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

United States, India, Russian Federation, Belgium, Spain, Israel, Croatia, Serbia, North Macedonia, South Africa, Slovenia, Brazil, Poland, Canada, Czechia
Novo Nordisk A/S

Completed

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus (DUAL™ VIII)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Italy, Mexico, Poland, Russian Federation, Slovakia, United Kingdom, Argentina, Norway, Turkey, Israel, Czechia, South Africa, Hungary, Brazil
Takeda

Completed

Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.

Diabetes Mellitus

United States, Australia, Brazil, Chile, Guatemala, India, Mexico, New Zealand, Peru, South Africa, Czech Republic, Germany, Hungary, Netherlands, Poland, Argentina
Mylan Pharmaceuticals Inc
Momenta Pharmaceuticals, Inc.

Completed

Extension Study of MYL-1701P-3001 for Safety and Efficacy

Diabetic Macular Edema

India
AstraZeneca

Terminated

GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes

Type 2 Diabetes

United States, Brazil, Czech Republic, Italy, Korea, Republic of, Russian Federation, South Africa, United Kingdom, Vietnam, Philippines, Malaysia, Estonia, Latvia, Lithuania, Poland, Finland, Canada, Hong Kong, Argentina, Hun... and more
Novo Nordisk A/S

Completed

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

Diabetes Mellitus, Type 2

India, United States, Thailand, Japan, Germany, Turkey, Hungary, Malaysia, Poland, South Africa, Czechia, Italy, France, Slovenia
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

Diabetes Mellitus, Type 2

Bangladesh, Belgium, Canada, China, Germany, Guatemala, Hong Kong, India, Lebanon, Mexico, Peru, Philippines, Spain, Taiwan
Astellas Pharma Inc

Completed

A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, India, Philippines, Colombia, Mexico
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2)

Diabetes Mellitus, Type 2 | Diabetes

India, Japan, Russian Federation, Spain, Sweden, Argentina, Hungary, Norway, South Africa, Turkey, Bulgaria, Romania, Thailand, Portugal, Hong Kong, Mexico, Ukraine, Czechia
Forest Laboratories
Phenomix

Terminated

Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone

Diabetes Mellitus, Type II

United States, Belarus, India, Romania, Germany, Lithuania
Novo Nordisk A/S

Active, not recruiting

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight (REDEFINE 2)

Obesity | Overweight | Type 2 Diabetes Mellitus

United States, India, Poland, Malaysia, United Kingdom, Japan, Thailand, Germany, Austria, Canada, Hungary, Ireland, Puerto Rico
Forest Laboratories
Phenomix

Terminated

Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin

Diabetes Mellitus, Type II

United States, Belarus, Colombia, Hungary, India, Lithuania, Peru, Romania
Novo Nordisk A/S

Completed

A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6) (ONWARDS 6)

Diabetes Mellitus, Type 1

United States, India, Italy, Russian Federation, United Kingdom, Canada, Netherlands, Austria, Japan, Spain, Germany, Turkey
Novo Nordisk A/S

Completed

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)

Diabetes Mellitus, Type 2

Croatia, India, Poland, Spain, Serbia, Germany, Slovakia, Slovenia, Turkey, Hungary, Greece, Czechia, Bulgaria, South Africa, Romania, Bosnia and Herzegovina, Estonia, Portugal, Latvia, Lithuania, North Macedonia
Eli Lilly and Company
Alkermes, Inc.

Completed

Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany, Puerto Rico, United Kingdom, Spain, Canada, Brazil, Korea, Republic of, India, Israel, Russian Federation, South Africa
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes (onset® 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Israel, Russian Federation, Slovakia, Canada, Serbia, United Kingdom, Puerto Rico
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 1)

Diabetes Mellitus, Type 2

United States, Croatia, India, Israel, Italy, Japan, Mexico, Poland, Puerto Rico, Russian Federation, Slovakia, Spain, United Kingdom
AstraZeneca

Completed

Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Diabetes

Taiwan, United States, Russian Federation, India
Sanofi
Hanmi Pharmaceutical Company Limited

Terminated

Effect of Efpeglenatide on Cardiovascular Outcomes (AMPLITUDE-O)

Type 2 Diabetes Mellitus

Estonia, Spain, Ukraine, Italy, Germany, Canada, Mexico, United States, Argentina, Bulgaria, Chile, Denmark, Finland, Hungary, India, Korea, Republic of, Latvia, Lithuania, Norway, Peru, Poland, Romania, Russian Federation, Serbia, Slov... and more
AstraZeneca

Terminated

GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate

Type 2 Diabetes

Brazil, France, Russian Federation, South Africa, Germany, Malaysia, Finland, Norway, Hong Kong, Canada, Hungary, Portugal, Taiwan, India, Philippines, Switzerland, Indonesia, Singapore
AstraZeneca

Completed

Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old

Diabetes Mellitus, Type 2

United States, Thailand, United Kingdom, Malaysia, New Zealand, Taiwan, Turkey, Canada, Mexico, Israel, India, Argentina, Brazil, Russian Federation, Australia, Korea, Republic of, Italy, Philippines, Colombia, Poland, Chile, Finland and more

Clinical Trials on Gestational Diabetes in India

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations